Synthetic data enriches clinical datasets and simulates alternative scientific scenarios through computer-generated subject data, synthetic placebo groups, digital twins, and more. Combined with AI across target identification, trial design, and sample size modeling, a new toolkit is emerging that could shorten the time from idea to decision, and animal health may be better placed than human pharma to use it.
- AI-driven target identification, trial design, and exploration of inclusion criteria
- Synthetic placebo groups, digital twins, and enriching underpowered datasets
- Real-world evidence and PIMS data as a development input
- Addressing small, fragmented datasets in guiding product development decisions
- Replacing, reducing and refining animal use through computational approaches
Speaker(s):

Margie Bell
Principal Biostatistician
Clindata
Time:
2:50pm-3:20pm
Agenda Track No.:
Track 8
Session Type:
General Session (Presentation)
Force Inline Description:
0